Advanced Flower Capital (AFCG) Q2 2026 Earnings Call Transcript

Advanced Flower Capital (AFCG) reported Q2 2026 net investment income of $3.5M ($0.15/share) vs $0.05/share distribution, with 3x coverage, and NAV per share rising to $8.25 from $7.90 (+$0.35) driven by investment income and repurchase accretion (+$0.17/share). Credit conditions remain a headwind: AFC highlighted rising private credit defaults (Fitch ~6% as of July 2026) and is actively pursuing Article 9 foreclosures for a Justice Grown loan in maturity default, alongside liquidation progress on legacy cannabis positions (e.g., Devi: $12.5M binding term sheet; DMA: 2/3 dispensary sales closed in July). On balance-sheet liquidity, AFC ended with $106.5M cash, 190% asset coverage (vs 150% requirement), net debt-to-equity of 0.53x (up from 0.48x), and repurchased 839k shares for ~$2.8M at $3.29/share.

Analysis

This is less a quarter about current earnings power than about whether management can convert a messy legacy book into a cleaner, higher-quality balance sheet faster than the market expects. The main positive is that buybacks below NAV mechanically raise per-share value and signal that management views the equity as mispriced; that matters more here than incremental originations because the stock is still being valued like a troubled credit cleanup, not a growing lender.

The real underwriting question is forward returns on redeployed capital. A 13%+ yield looks attractive only if realized losses stay contained; with defaults rising across private credit, the spread premium can disappear quickly if one or two credits sour. The next 1-3 months are about asset-sale closes and whether the balance sheet actually migrates toward more productive leverage; over 6-18 months, the key is whether lower middle market deployment can replace runoff without sacrificing credit quality.

Contrarianly, the market may be over-penalizing the equity for cannabis exposure while underestimating the optionality from a deeply discounted stock plus liquidity. But the opposite risk is that the discount is rational: if the legacy wind-down drags, the company can look optically cheap for a long time while NAV accretion comes from buybacks rather than sustainable earnings growth. The thesis is falsified if NAV/share stops rising, nonaccrual resolution stalls, or leverage is rebuilt before recurring income stabilizes.

Key Decisions for Investors

• Start a small tactical long AFCG only on weakness; the risk/reward is acceptable because repurchases below NAV provide near-term downside support, but size it as a special-situation position rather than a core credit hold.
• Do not chase the first post-earnings move; wait 3-5 sessions for the market to separate buyback-driven optics from actual redeployment, since the next catalyst is more likely to be a portfolio update than the quarter itself.
• If AFCG options are liquid, sell 6-9 month cash-secured puts struck near the recent buyback level to get paid while demanding a lower entry price; exit if legacy loan resolutions slip or NAV/share flattens next quarter.
• Set a hard falsifier: cut the thesis if Q3 shows lower NAV/share, rising nonaccruals, or higher leverage without commensurate recurring income, because then the balance sheet is being stretched before the cleanup is finished.